<DOC>
	<DOC>NCT02581072</DOC>
	<brief_summary>The study is a 4 way cross-over study in subjects with moderate to severe acne vulgaris who will each receive SB204 4%, a supratherapeutic dose of SB204 (either 8 or 12%), moxifloxacillin (positive control) and appropriate placebo to match. SB204 will be applied topically to the upper back, upper chest, upper shoulders, and face.</brief_summary>
	<brief_title>A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204</brief_title>
	<detailed_description />
	<mesh_term>Acne Vulgaris</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
	<criteria>Moderate to severe acne 20 inflammatory and 25 noninflammatory acne lesions Pregnant, trying to become pregnant, or nursing Known allergy to any component of the topical SB204 formulation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>